Author

A. A. Melcher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Patrikeev· 2 shared E. B. Wilson· 2 shared E. C. Patin· 2 shared G. P. Cook· 2 shared J. Kyula· 2 shared K. J. Harrington· 2 shared M. McLaughlin· 2 shared M. Pedersen· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Patrikeev

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling.

E. Armstrong, M. K. L. Chiu, S. Foo, L. Appleton, P. Nenclares, A. Patrikeev, N. Mohan, M. McLaughlin, G. Bozhanova, J. Hoebart, V. Roulstone, E. C. Patin, M. Pedersen, J. Kyula, F. Errington-Mais, , V. A. Jennings

This study shows that combining oncolytic Maraba virus with PD-1 blockade overcomes resistance in advanced melanoma with a cold tumor microenvironment.

bioRxiv · Apr 2, 2024Cancer Biology

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

E. C. Patin, P. Nenclares, C. Chan Wah Hak, M. T. Dillon, A. Patrikeev, M. McLaughlin, L. Grove, S. Foo, H. Soliman, J. P. Barata, J. Marsden, H. Baldock, V. Roulstone, J. Kyula, A. Burley, , K. J. Harrington

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

bioRxiv · Nov 8, 2023 · PreprintImmunology

Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity

M. Wantoch, E. B. Wilson, A. P. Droop, S. L. Phillips, M. Coffey, Y. M. El-Sherbiny, T. D. Holmes, A. A. Melcher, L. F. Wetherill, G. P. Cook

This study shows reovirus treatment affects CD56dim and CD56bright NK cell subsets differently, modulating their activity and signaling pathways in vivo.

bioRxiv · Dec 16, 2020 · PreprintImmunology

Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered natural killer cell phenotype in glioblastoma

H. J. Close, L. F. Stead, J. Nsengimana, K. Reilly, A. Droop, H. Wurdak, R. K. Mathew, R. Corns, J. A. Newton-Bishop, A. A. Melcher, S. C. Short, G. P. Cook, E. B. Wilson

bioRxiv · Oct 4, 2019Immunology